- 全部删除
您的购物车当前为空
Tislelizumab (BGB-A317) 是一种靶向人程序性死亡受体-1(PD-1)IgG4类单克隆抗体,具有抗肿瘤活性,抑制 Fcγ 受体与巨噬细胞的结合,可用于研究晚期鳞状非小细胞肺癌。

为众多的药物研发团队赋能,
让新药发现更简单!
Tislelizumab (BGB-A317) 是一种靶向人程序性死亡受体-1(PD-1)IgG4类单克隆抗体,具有抗肿瘤活性,抑制 Fcγ 受体与巨噬细胞的结合,可用于研究晚期鳞状非小细胞肺癌。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 993 | In stock | |
| 5 mg | ¥ 2,880 | In stock | |
| 10 mg | ¥ 4,560 | In stock | |
| 25 mg | ¥ 6,900 | In stock | |
| 50 mg | ¥ 9,490 | In stock | |
| 100 mg | ¥ 12,800 | In stock |
Tislelizumab 相关产品
| 产品描述 | Tislelizumab (BGB-A317) is an IgG4 class monoclonal antibody targeting human programmed death receptor-1 (PD-1) with antitumor activity that inhibits the binding of Fcγ receptor to macrophages and can be used to study advanced squamous non-small cell lung cancer. |
| 别名 | 替雷利珠单抗, VDT-482, BGB-A317 |
| CAS No. | 1858168-59-8 |
| 颜色 | Transparent |
| 物理性状 | Liquid |
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容